Gilead Sciences, Inc. $GILD Holdings Decreased by Coppell Advisory Solutions LLC

Key Points

• Coppell Advisory Solutions LLC has reduced its holdings in Gilead Sciences by 33.4%, selling 11,719 shares, and now owns 23,323 shares valued at approximately $2.43 million.
• Several hedge funds increased their positions in Gilead, with significant percentage increases, reflecting strong institutional interest as 83.67% of the stock is held by institutional investors.
• Wall Street analysts have a strong outlook for Gilead, with multiple upgrades in ratings and price targets, resulting in an average rating of "Moderate Buy" and a target price of $115.39.

Coppell Advisory Solutions LLC reduced its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 33.4% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 23,323 shares of the biopharmaceutical company's stock after selling 11,719 shares during the period. Coppell Advisory Solutions LLC's holdings in Gilead Sciences were worth $2,430,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Nissay Asset Management Corp Japan ADV lifted its holdings in shares of Gilead Sciences by 5.2% during the 4th quarter. Nissay Asset Management Corp Japan ADV now owns 284,243 shares of the biopharmaceutical company's stock worth $26,750,000 after acquiring an additional 14,009 shares during the period. Ariel Investments LLC lifted its stake in shares of Gilead Sciences by 7.7% in the 1st quarter. Ariel Investments LLC now owns 430,424 shares of the biopharmaceutical company's stock valued at $48,229,000 after purchasing an additional 30,630 shares in the last quarter. Golden State Wealth Management LLC lifted its stake in shares of Gilead Sciences by 14.5% in the 1st quarter. Golden State Wealth Management LLC now owns 863 shares of the biopharmaceutical company's stock valued at $97,000 after purchasing an additional 109 shares in the last quarter. Mufg Securities Americas Inc. acquired a new position in shares of Gilead Sciences in the 4th quarter valued at about $1,699,000. Finally, ASR Vermogensbeheer N.V. acquired a new position in shares of Gilead Sciences in the 1st quarter valued at about $11,688,000. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Gilead Sciences Stock Down 2.8%

Shares of NASDAQ:GILD traded down $3.31 during mid-day trading on Friday, hitting $114.55. 6,466,956 shares of the company traded hands, compared to its average volume of 5,830,447. The firm has a market cap of $142.13 billion, a P/E ratio of 22.82, a PEG ratio of 0.80 and a beta of 0.36. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. Gilead Sciences, Inc. has a 52-week low of $81.57 and a 52-week high of $121.83. The firm's 50 day simple moving average is $114.04 and its 200 day simple moving average is $110.09.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The company had revenue of $7.08 billion for the quarter, compared to the consensus estimate of $6.95 billion. During the same period in the previous year, the business earned $2.01 EPS. Gilead Sciences's revenue for the quarter was up 1.4% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, equities analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, September 29th. Shareholders of record on Monday, September 15th will be issued a dividend of $0.79 per share. The ex-dividend date is Monday, September 15th. This represents a $3.16 annualized dividend and a yield of 2.8%. Gilead Sciences's payout ratio is currently 62.95%.

Insiders Place Their Bets

In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $118.53, for a total transaction of $3,318,840.00. Following the sale, the insider directly owned 114,168 shares in the company, valued at $13,532,333.04. The trade was a 19.70% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Daniel Patrick O'day sold 10,000 shares of Gilead Sciences stock in a transaction that occurred on Thursday, August 28th. The stock was sold at an average price of $113.63, for a total value of $1,136,300.00. Following the sale, the chief executive officer owned 595,725 shares in the company, valued at $67,692,231.75. This represents a 1.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 82,000 shares of company stock valued at $9,371,330 over the last 90 days. 0.27% of the stock is owned by company insiders.

Analyst Ratings Changes

GILD has been the topic of several research analyst reports. Daiwa Capital Markets raised Gilead Sciences from a "neutral" rating to an "outperform" rating and set a $128.00 price objective on the stock in a research note on Tuesday, August 19th. UBS Group lifted their price objective on Gilead Sciences from $108.00 to $112.00 and gave the company a "neutral" rating in a research note on Friday, August 8th. Needham & Company LLC raised Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price objective on the stock in a research note on Friday, July 25th. Truist Financial upgraded Gilead Sciences from a "hold" rating to a "buy" rating and raised their target price for the company from $108.00 to $127.00 in a report on Friday, August 8th. Finally, Daiwa America upgraded Gilead Sciences from a "hold" rating to a "strong-buy" rating in a report on Tuesday, August 19th. Three analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have issued a Hold rating to the company's stock. Based on data from MarketBeat, Gilead Sciences has an average rating of "Moderate Buy" and a consensus target price of $115.39.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.